JP2022525661A5 - - Google Patents
Info
- Publication number
- JP2022525661A5 JP2022525661A5 JP2021556442A JP2021556442A JP2022525661A5 JP 2022525661 A5 JP2022525661 A5 JP 2022525661A5 JP 2021556442 A JP2021556442 A JP 2021556442A JP 2021556442 A JP2021556442 A JP 2021556442A JP 2022525661 A5 JP2022525661 A5 JP 2022525661A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- seq
- sequence
- amino acid
- protein according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19163970.7A EP3711772A1 (en) | 2019-03-20 | 2019-03-20 | Recombinant proteins and fusion proteins |
| EP19163970.7 | 2019-03-20 | ||
| PCT/EP2020/057773 WO2020188081A1 (en) | 2019-03-20 | 2020-03-20 | Recombinant ccn domain proteins and fusion proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022525661A JP2022525661A (ja) | 2022-05-18 |
| JP2022525661A5 true JP2022525661A5 (cg-RX-API-DMAC7.html) | 2023-03-28 |
| JP7600135B2 JP7600135B2 (ja) | 2024-12-16 |
Family
ID=66102364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021556442A Active JP7600135B2 (ja) | 2019-03-20 | 2020-03-20 | 組換えｃｃｎドメインタンパク質および融合タンパク質 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12606602B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3711772A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7600135B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210142681A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113747912B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020243073B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021017147A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3133740A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL285930B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021011407A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202109738QA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020188081A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023552810A (ja) * | 2020-12-08 | 2023-12-19 | シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） | 抗ｅｇｆｒキメラ抗原受容体 |
| GB202212077D0 (en) | 2022-08-18 | 2022-10-05 | Tribune Therapeutics Ab | Agents that inhibit ccn ligand-induced signalling for treating disease |
| GB202400055D0 (en) * | 2024-01-03 | 2024-02-14 | Tribune Therapeutics Ab | Use of ccn domain-containing proteins for the treatment of disease |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT88641B (pt) | 1987-10-02 | 1993-04-30 | Genentech Inc | Metodo para a preparacao de uma variante de adesao |
| GB8909916D0 (en) | 1989-04-29 | 1989-06-14 | Delta Biotechnology Ltd | Polypeptides |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| WO1999047556A2 (en) * | 1998-03-19 | 1999-09-23 | Trustees Of Tufts College | Novel heparin-induced ccn-like molecules and uses therefor |
| EP1326980B1 (en) * | 2000-10-16 | 2008-03-19 | Genentech, Inc. | Methods of treatment using wisp polypeptides |
| CN1835763B (zh) | 2003-06-20 | 2011-04-20 | 妙甯公司 | Ccn1组合物和方法 |
| FR2858234B1 (fr) | 2003-08-01 | 2007-09-14 | Centre Nat Rech Scient | Nouvel agent anti-angiogenique et son utilisation, notamment dans le cadre du traitement des cancers |
| EP1771467A2 (en) | 2004-07-26 | 2007-04-11 | Asterion Limited | Linkers |
| ATE506961T1 (de) * | 2005-01-10 | 2011-05-15 | Univ Rosalind Franklin Medicine & Science | Ccn3 proteine zur behandlung und diagnose von nierenerkrankungen |
| CN101146826A (zh) | 2005-01-24 | 2008-03-19 | 得克萨斯大学体系董事会 | 与磷脂酰丝氨酸结合的fc融合构建体及其治疗用途 |
| EP2015781A4 (en) * | 2005-09-12 | 2009-12-23 | Univ Johns Hopkins | COMPOSITIONS HAVING ANTIANGIOGENIC ACTIVITY AND USES THEREOF |
| JP2009067678A (ja) * | 2005-12-07 | 2009-04-02 | Nihon Nosan Kogyo Kk | 結合組織増殖因子に対する抗体又はそれを含む組成物 |
| US20080207489A1 (en) | 2007-02-21 | 2008-08-28 | John Castellot | Use of CCN5 for treatment of smooth muscle proliferation disorders |
| WO2009086132A2 (en) | 2007-12-20 | 2009-07-09 | University Of Southern California | Design of spacers to increase the expression of recombinant fusion proteins |
| DK3061817T3 (en) * | 2009-04-30 | 2019-03-04 | Kao Corp | Alkaline protease variants |
| TW201102086A (en) | 2009-06-04 | 2011-01-16 | Hoffmann La Roche | Antibodies against human CCN1 and uses thereof |
| JP5820378B2 (ja) * | 2009-09-09 | 2015-11-24 | ファーマイン コーポレーションＰｈａｒｍａｉｎ Ｃｏｒｐｏｒａｔｉｏｎ | 治療剤の送達のための陰イオンコア組成物およびその製造ならびに使用方法 |
| MX340971B (es) | 2009-11-23 | 2016-08-02 | Amgen Inc * | Fragmento cristalizable (fc) de anticuerpo monomerico. |
| KR101187814B1 (ko) | 2010-03-22 | 2012-10-08 | 광주과학기술원 | 심부전 예방 또는 치료용 약제학적 조성물 및 심부전 예방 또는 치료제의 스크리닝 방법 |
| JP5939584B2 (ja) | 2010-04-02 | 2016-06-22 | ロザリンド フランクリン ユニバーシティー オブ メディスン アンド サイエンス | 治療用ｃｃｎ３ペプチドおよびそれらの類似体 |
| US9114112B2 (en) * | 2010-04-02 | 2015-08-25 | Rosalind Franklin University Of Medicine And Science | CCN3 and CCN3 peptides and analogs thereof for therapeutic uses |
| PT2621515T (pt) * | 2010-09-28 | 2017-07-12 | Aegerion Pharmaceuticals Inc | Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada |
| ES2623912T3 (es) | 2010-12-23 | 2017-07-12 | Janssen Biotech, Inc. | Mutantes FC de anticuerpo activo resistente a proteasa |
| WO2014008582A1 (en) | 2012-07-11 | 2014-01-16 | The University Of Western Ontario | Method of treating wounds with penostin and/or ccn2 |
| US20140271641A1 (en) | 2013-03-14 | 2014-09-18 | University Of Guelph | Thrombospondin-1 polypeptides and methods of using same |
| GB201316592D0 (en) | 2013-09-18 | 2013-10-30 | Levicept Ltd | Fusion protein |
| AU2016228806B2 (en) | 2015-03-12 | 2020-10-22 | Medimmune, Llc | Method of purifying albumin-fusion proteins |
| JP2018517708A (ja) | 2015-06-05 | 2018-07-05 | ニューヨーク・ユニバーシティ | 抗ブドウ球菌生物学的薬剤のための組成物及び方法 |
| GB201512733D0 (en) | 2015-07-20 | 2015-08-26 | Genagon Therapeutics Ab | Therapeutic agents for treating conditions associated with elevated GDF15 |
| CN105396136B (zh) * | 2015-11-23 | 2018-10-30 | 上海交通大学医学院附属第九人民医院 | CCN1（Cyr61）在治疗皮肤损伤及皮肤萎缩相关疾病中的应用 |
| EP3192806A1 (en) | 2016-01-13 | 2017-07-19 | Affiris AG | Alpha chain of the high-affinity ige receptor (fceria) |
| CA3011887C (en) | 2016-03-14 | 2024-10-29 | Universitetet I Oslo | Genetically transformed immunoglobulins with altered FCRN binding |
| US10028906B2 (en) | 2016-03-22 | 2018-07-24 | Rosalind Franklin University Of Medicine And Science | Method and kit for treating a solid tumor and associated desmoplasia |
| US11795202B2 (en) | 2016-08-04 | 2023-10-24 | Stichting Vumc | Fusion polypeptide comprising a foreign antigen and self antigen |
| US20180127478A1 (en) | 2016-09-16 | 2018-05-10 | Wei-Chiang Shen | SINGLE CHAIN Fc-DIMER-HUMAN GROWTH HORMONE FUSION PROTEIN FOR IMPROVED DRUG DELIVERY |
| KR20180099537A (ko) * | 2017-02-28 | 2018-09-05 | 주식회사 파이안바이오테크놀로지 | 근섬유모세포의 병리적 활성이 초래하는 섬유증식성 질병 치료제 |
| KR102008407B1 (ko) | 2017-09-05 | 2019-08-08 | 한국생명공학연구원 | 코돈 최적화된 il-21 및 이의 용도 |
| WO2019071007A1 (en) | 2017-10-05 | 2019-04-11 | New York Genome Center, Inc. | METHODS AND COMPOSITIONS FOR TARGETING VASCULAR MIMETTISM |
-
2019
- 2019-03-20 EP EP19163970.7A patent/EP3711772A1/en not_active Withdrawn
-
2020
- 2020-03-20 AU AU2020243073A patent/AU2020243073B2/en active Active
- 2020-03-20 BR BR112021017147A patent/BR112021017147A2/pt unknown
- 2020-03-20 IL IL285930A patent/IL285930B2/en unknown
- 2020-03-20 US US17/440,576 patent/US12606602B2/en active Active
- 2020-03-20 WO PCT/EP2020/057773 patent/WO2020188081A1/en not_active Ceased
- 2020-03-20 CN CN202080023396.5A patent/CN113747912B/zh active Active
- 2020-03-20 CA CA3133740A patent/CA3133740A1/en active Pending
- 2020-03-20 KR KR1020217033515A patent/KR20210142681A/ko not_active Ceased
- 2020-03-20 EP EP20711209.5A patent/EP3941507A1/en active Pending
- 2020-03-20 JP JP2021556442A patent/JP7600135B2/ja active Active
- 2020-03-20 SG SG11202109738Q patent/SG11202109738QA/en unknown
- 2020-03-20 MX MX2021011407A patent/MX2021011407A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240368236A1 (en) | Growth differentiation factor 15 (gdf-15) constructs | |
| JP7128246B2 (ja) | 抗炎症活性を有するペプチド、及びそれを含む組成物 | |
| JP2021510162A5 (cg-RX-API-DMAC7.html) | ||
| JP2022525661A5 (cg-RX-API-DMAC7.html) | ||
| JP2018171063A5 (cg-RX-API-DMAC7.html) | ||
| CN114206908B (zh) | 具有改善的稳定性的经设计的锚蛋白重复结构域 | |
| RU2006146995A (ru) | Химерные белки, ингибирующие ангиогенез, и их применение | |
| CN100390201C (zh) | 具有增强红细胞生成素体内活性的融合蛋白 | |
| WO1990013306A2 (en) | Small polypeptides | |
| ES3011833T3 (en) | Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling | |
| JP2015504052A5 (cg-RX-API-DMAC7.html) | ||
| JP2010504336A5 (cg-RX-API-DMAC7.html) | ||
| JP2023179752A5 (cg-RX-API-DMAC7.html) | ||
| WO2018077098A1 (zh) | 一种用于治疗肠道疾病的融合蛋白 | |
| CN103641896A (zh) | 明胶样单元的用途 | |
| Kuo et al. | Orientation of type VI collagen monomers in molecular aggregates | |
| WO2023280133A1 (zh) | 融合蛋白及其应用 | |
| JP2020518613A5 (cg-RX-API-DMAC7.html) | ||
| JP2022532445A (ja) | 新規な中間体製造による持続型薬物結合体の製造方法 | |
| CN118076373A (zh) | 用于联合疗法的包括生长分化因子-15变体和胰高血糖素样肽-1受体激动剂的组合物 | |
| JP2024543158A5 (cg-RX-API-DMAC7.html) | ||
| JP2017501970A (ja) | 薬学的活性エンティティのマルチサブユニット構造への標的特異的送達のためのマルチサブユニット構造のサブユニットの結合ドメインの使用 | |
| RU2021125671A (ru) | Рекомбинантные белки с доменами ccn и слитые белки | |
| TWI857985B (zh) | 胜肽之結合物及其製造方法 | |
| US20200031895A1 (en) | Stabilized proteolytically activated growth differentiation factor 11 |